Managing Barrett's esophagus with radiofrequency ablation
Open Access
- 8 March 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 1 (2) , 95-104
Abstract
Barrett's esophagus (BE) is a well-established pre-malignant lesion for esophageal adenocarcinoma, a condition that carries a dismal five-year overall survival rate of less than 15%. Among several available methods to eliminate BE, radiofrequency ablation (RFA) provides the most efficient modality, since it has been demonstrated to successfully eradicate BE with or without dysplasia with acceptable safety, efficacy and durability profiles. In conjunction with proton pump therapy, this new technology has quickly become the standard care for patients with dysplastic BE. However, several technical questions remain about how to deploy RFA therapy for maximum effectiveness and long-term favorable outcomes for all stages of the disease. These include how to select patient for therapy, what the best protocol for RFA is, when to use other modalities, such as endoscopic mucosal resection, and what should be considered for refractory BE. This review addresses these questions with the perspective of the best available evidence matched with the authors' experience with the technology.Keywords
This publication has 100 references indexed in Scilit:
- Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos)Gastrointestinal Endoscopy, 2012
- The Risk of Lymph-Node Metastases in Patients With High-Grade Dysplasia or Intramucosal Carcinoma in Barrett's Esophagus: A Systematic ReviewAmerican Journal of Gastroenterology, 2012
- Buried Metaplasia After Endoscopic Ablation of Barrett's Esophagus: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trialGastrointestinal Endoscopy, 2011
- Durability of Radiofrequency Ablation in Barrett's Esophagus With DysplasiaGastroenterology, 2011
- Detection of Intestinal Metaplasia After Successful Eradication of Barrett’s Esophagus with Radiofrequency AblationDigestive Diseases and Sciences, 2011
- American Gastroenterological Association Technical Review on the Management of Barrett's EsophagusGastroenterology, 2011
- Comparison of Endoscopic and Clinical Characteristics of Patients with Familial and Sporadic Barrett’s EsophagusDigestive Diseases and Sciences, 2011
- A Cost-Utility Analysis of Ablative Therapy for Barrett's EsophagusGastroenterology, 2009
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression riskOncogene, 2005